

FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attorney Docket: 1004263.156US	Serial No.: 10/076,674
	Applicant: Kenneth Sokoll	
	Filing Date: February 14, 2002	Group Art Unit: 1648

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication / Issue Date	Name	Class	Sub-Class	Filing Date

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)

	STERN, B. et al, "Vaccination with Tumor Peptide in CpG Adjuvant Protects Via IFN--Dependent CD4 Cell Immunity" <i>J. Immunology</i> (2002), 168:6099-6105
	MAURER, TA, et al, "CpG-DNA aided cross-presentation of soluble antigens by dendritic cells." <i>Eur. J. Immunol.</i> (2002), 32:2356-2364
	SINGH, M. et al, "Recent advances in vaccine adjuvants" <i>Pharmaceutical Research</i> , (2002), 19(6):715-728
	O'HAGEN, DT, et al, "Recent developments in adjuvants for vaccines against infectious diseases" <i>Biomolecular Engineering</i> (2001), 18:69-85
	SINGH, M, et al, "Recent advances in veterinary vaccine adjuvants" <i>International J. Parasitology</i> , (2003), 33:469-478
	O'HAGEN, DT, "Recent Developments in Vaccine Delivery Systems" <i>Current Drug Targets-Infectious Disorders</i> (2001), 1:273-286
	DITTMER, U, et al, "Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs" <i>Current Opinion in Microbiology</i> , (2003), 6:472-477
	YOSHINAGA, T, et al, "DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells" <i>Immunology</i> , (2006), 120:295-302
	RIEDL, P, et al, "Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines" <i>J. Mol. Med.</i> , (2004), 82:144-152
	DIMINSKY, D, et al, "Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles" <i>Vaccine</i> , (2000), 18:3-17
	MORITA, T, et al, "Preparation of gelatin microparticles by co-lyophilization with poly(ethylene glycol): characterization and application to entrapment into biodegradable microspheres" <i>International J. Pharmaceutics</i> (2001), 219:127-137
	IVINS, B, et al, "Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol <i>Bacillus anthracis</i> spore challenge in guinea pigs" <i>Vaccines</i> , (1995), 13/18:1779-1784
	GUPTA, RK, et al, "Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid" <i>Vaccine</i> , (1997), 15(6/7):672-678
	HAKIM, I, et al, "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines" <i>J. Immunol.</i> , (1996), 157:5503-5511
	ZENG, XY, et al, "Effects of active immunization against GnRH on serum LH, inhibin A, sexual development and growth rate in Chinese female pigs" <i>Theriogenology</i> (2002), 58:1315-1326
	PROIETTI, E. et al, "Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza Vaccine Model" <i>J. Immunol.</i> , (2002), 169:375-383
	"Foot and Mouth Disease" in OIE Manual of Standards for Diagnostic Tests and Vaccines, publisher: Springer Netherlands, Ch. 2.1.1, (1997)
	NESBURN, AB, et al, "Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant" <i>Vaccine</i> , (2005), 23:873-883

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	